BEAUTIFUL TRIAL IVABRADINE PDF

Objectives: Ivabradine is a selective heart rate-lowering agent that acts by inhibiting the pacemaker current If in sinoatrial node cells. Patients with coronary artery disease and left ventricular dysfunction are at high risk of death and cardiac events, and the BEAUTIFUL study was designed to evaluate the effects of ivabradine on outcome in such patients receiving optimal medical therapy. This report describes the study population at baseline. Results: A total of 10, patients were randomized.

Author:Gutaur Gacage
Country:Spain
Language:English (Spanish)
Genre:Education
Published (Last):4 June 2015
Pages:117
PDF File Size:4.56 Mb
ePub File Size:5.65 Mb
ISBN:576-2-59203-689-4
Downloads:91994
Price:Free* [*Free Regsitration Required]
Uploader:Viran



The goal of the trial was to evaluate treatment with the sinoatrial node inhibitor, ivabradine, compared with placebo in patients with stable coronary artery disease and left ventricular dysfunction. Composite of cardiovascular death, hospital admission for myocardial infarction, or for new onset or worsening heart failure. The dose of ivabradine was 5 mg twice daily for 2 weeks, and then titrated to 7. The dose was decreased or stopped if the heart rate was less than 50 bpm.

The mean heart rate at enrollment was Serious adverse events occurred in The difference in the mean heart rate placebo minus ivabradine at 12 months was 6.

Among patients with a baseline heart rate greater than 70 bpm, the mean difference was 7. The primary outcome, composite of cardiovascular death, hospital admission for myocardial infarction, or for new onset or worsening heart failure occurred in Among patients with a baseline heart rate greater than 70 bpm, the primary outcome occurred in All-cause mortality occurred in Ivabradine produces a sustained reduction in heart rate over long-term follow-up.

Among patients with stable coronary artery disease and left ventricular dysfunction, the use of ivabradine does not improve cardiac outcomes compared with placebo. Ivabradine was well tolerated, with a similar rate of adverse events compared with control. The motivation for the use of this agent was the ability of ivabradine to reduce heart rate without affecting blood pressure, contractility, or ventricular depolarization.

It remains to be seen if ivabradine would have produced different results in a population with a higher resting heart rate i. Lancet ; Presented by Dr. Description: The goal of the trial was to evaluate treatment with the sinoatrial node inhibitor, ivabradine, compared with placebo in patients with stable coronary artery disease and left ventricular dysfunction. Hypothesis: Ivabradine will improve cardiac death and morbidity. Concomitant Medications: The dose of ivabradine was 5 mg twice daily for 2 weeks, and then titrated to 7.

Interpretation: Ivabradine produces a sustained reduction in heart rate over long-term follow-up. Share via:. Media Center ACC. All rights reserved.

BLUSENS K20 MANUAL PDF

BEAUTIFUL TRIAL

No account yet? Start here. Munich, Germany, 31 August, The results of the much awaited BEAUTIFUL morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction trial have shown that coronary artery disease CAD patients with left ventricular dysfunction LVD and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients heart rate above 70 bpm treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy. With the BEAUTIFUL results, ivabradine is the first antianginal treatment shown to reduce myocardial infarction and revascularisation and to have a good tolerability profile even when used with other drugs. The mean heart rate in these patients was 71 bpm and half of the patients had a heart rate more than 70 bpm. In the overall study population treatment with ivabradine did not result in a significant reduction of the primary composite end point Cardiovascular death, admission to hospital for acute MI and admission to hospital for heart failure.

EL MACEDONIO NICHOLAS GUILD PDF

Study record managers: refer to the Data Element Definitions if submitting registration or results information. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.

BORN TO BITE LYNSAY SANDS PDF

.

Related Articles